CD8A and prostate neoplasm: CD8+–CD4+ T-cell ratios revealed that untreated prostate tumors contained twice as many CD8+ T cells than CD4+ T cells, while CPG-1668 treatment resulted in more CD4+ T cells, although the cell numbers here were very low.